reviva pharmaceuticals is a pharmaceuticals company located in 5941 optical ct, san jose, california, united states.
Company profile
Ticker
RVPH
Exchange
Website
CEO
Rahul Nayar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Tenzing Acquisition Corp.
SEC CIK
RVPH stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
14 Feb 24
424B4
Prospectus supplement with pricing info
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
S-3
Shelf registration
2 Feb 24
8-K
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
17 Nov 23
424B5
Prospectus supplement for primary offering
17 Nov 23
8-K/A
Changes in Registrant's Certifying Accountant
14 Nov 23
8-K
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Latest ownership filings
SC 13D/A
Bhat Laxminarayan
16 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
VEDANTA PARTNERS, LLC
30 Nov 23
4
PARAG SAXENA
22 Nov 23
4
Leslie D. Funtleyder
14 Nov 23
4
PARAG SAXENA
14 Nov 23
4
Richard A Margolin
14 Nov 23
4
Purav Patel
14 Nov 23
SC 13D/A
Bhat Laxminarayan
5 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Feb 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.97 mm | 4.97 mm | 4.97 mm | 4.97 mm | 4.97 mm | 4.97 mm |
Cash burn (monthly) | 2.06 mm | 1.52 mm | 3.57 mm | 3.17 mm | 2.06 mm | 2.01 mm |
Cash used (since last report) | 12.31 mm | 9.07 mm | 21.33 mm | 18.92 mm | 12.31 mm | 12.02 mm |
Cash remaining | -7.33 mm | -4.10 mm | -16.36 mm | -13.94 mm | -7.33 mm | -7.05 mm |
Runway (months of cash) | -3.6 | -2.7 | -4.6 | -4.4 | -3.6 | -3.5 |
Institutional ownership, Q3 2023
27.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 1 |
Closed positions | 25 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 250.97 mm |
Total shares | 7.62 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vedanta Partners | 5.19 mm | $11.43 mm |
Tang Capital Partners | 2.27 mm | $0.00 |
Arena Investors | 85.00 k | $130.90 mm |
Walleye Capital | 33.72 k | $51.93 mm |
Walleye Trading | 25.73 k | $39.62 mm |
National Asset Management | 11.10 k | $17.10 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Nov 23 | Parag Saxena | Common Stock Warrant Common Stock | Other | Acquire J | Yes | No | 5 | 585,366 | 2.93 mm | 585,366 |
20 Nov 23 | Parag Saxena | Pre-Funded Warrant Common Stock | Other | Acquire J | Yes | No | 0.0001 | 585,366 | 58.54 | 585,366 |
13 Nov 23 | Parag Saxena | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 6.04 | 8,200 | 49.53 k | 8,200 |
13 Nov 23 | Richard A Margolin | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 6.04 | 8,200 | 49.53 k | 8,200 |
13 Nov 23 | Funtleyder Leslie D. | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 6.04 | 8,200 | 49.53 k | 8,200 |
13 Nov 23 | Purav Patel | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 6.04 | 8,200 | 49.53 k | 8,200 |
News
Reviva to Present RECOVER Phase 3 Clinical Trial Data For Brilaroxazine In Schizophrenia At The ASCPT 2024 Annual Meeting
26 Mar 24
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target
25 Mar 24
Reviva to Host KOL Event To Discuss Topline Data From Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia
6 Feb 24
Reviva Provides Corporate And Program Updates And Highlights Key Upcoming Milestones
4 Jan 24